Table 4.
Serum luteinizing hormone, follicle-stimulating hormone, and progesterone concentrations following administration of COC alone or COC and erenumab
| COC alone | COC and erenumab | Difference (COC and erenumab vs COC alone) | |
|---|---|---|---|
| Luteinizing hormone (IU/L) | |||
| Median (1st quartile, 3rd quartile)a | 3.4 (1.0, 6.3) | 3.6 (1.9, 5.7) | − 0.2 (− 1.6, 1.1) |
| Mean (SD)a | 4.5 (5.8) | 4.6 (4.9) | 0.2 (3.1) |
| Follicle-stimulating hormone (IU/L) | |||
| Median (1st quartile, 3rd quartile)a | 3.1 (2.2, 4.4) | 4.0 (1.4, 5.3) | 0.3 (− 0.7, 2.0) |
| Mean (SD)a | 3.4 (2.1) | 4.3 (3.0) | 1.2 (3.2) |
| Progesterone (nmol/L) | |||
| Median (1st quartile, 3rd quartile)b | 1.8 (1.1, 2.3) | 2.2 (1.3, 4.3) | 0.33 (− 1.3, 2.0) |
| Mean (SD)b | 4.8 (12.2) | 3.7 (3.7) | − 2.4 (13.9) |
| Median (1st quartile, 3rd quartile)c | 2.2 (1.6, 10.4) | 0.03 (− 0.9, 7.9) | |
| Mean (SD)c | 13.3 (22.1) | 3.1 (10.7) | |
| Median (1st quartile, 3rd quartile)d | 1.5 (1.4, 1.9) | − 0.29 (− 0.6, 0.3) | |
| Mean (SD)d | 6.1 (12.9) | 0.9 (3.8) | |
Data represent median (1st quartile, 3rd quartile)
COC combined oral contraceptive, SD standard deviation
Samples collected on:
aDay 14 of cycle 2 (COC alone) and cycle 3 (COC and erenumab)
bDay 21 of cycle 2 (COC alone) and Day 21 of cycle 3 (COC and erenumab)
cStudy day 105
dStudy day 133